Sarcoma clinical trials

65 trials changed in the last 30 days: 6 stopped, 37 with notable changes, 22 with minor changes only.

1. Stopped

   Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent…Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants

   Trial terminated

   Also in this update: Study completion date changed from estimate of Jul 2028 to Jun 19, 2026; Final enrollment: 5 participants (planned 40)

   Iovance Biotherapeutics, Inc.·Phase 1· NCT06566092· Registry history of NCT06566092 on ClinicalTrials.gov (opens the registry)

   Oct 16, 2026

2. Stopped

   DIT309 in Advanced Bone and Soft Tissue Sarcomas

   Recruitment suspended

   Tcelltech Inc.·Phase 1· NCT07052383· Registry history of NCT07052383 on ClinicalTrials.gov (opens the registry)

   Oct 14, 2026

3. Stopped

   New Combination of Anti-cancer Drugs in Patients Newly Diagnosed…New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body

   Trial terminated

   Also in this update: Study completion date changed from estimate of Aug 19, 2027 to Sep 22, 2026

   Children's Oncology Group·Phase 2/3· NCT06820957· Registry history of NCT06820957 on ClinicalTrials.gov (opens the registry)

   Oct 5, 2026

4. Stopped

   Digital Art Therapy for Young Cancer Survivors

   Trial terminated

   Also in this update: Primary completion date changed from estimate of Apr 2027 to Aug 28, 2026; Final enrollment: 2 participants (planned 15)

   UNC Lineberger Comprehensive Cancer Center·Not applicable· NCT06789666· Registry history of NCT06789666 on ClinicalTrials.gov (opens the registry)

   Oct 15, 2026

5. Stopped

   RP2 and Tivozanib · Metastatic Renal Cell Cancer After Progression…RP2 and Tivozanib · Metastatic Renal Cell Cancer After Progression on Immunotherapy

   Withdrawn before enrolling

   City of Hope Medical Center·Phase 2· NCT07218692· Registry history of NCT07218692 on ClinicalTrials.gov (opens the registry)

   Oct 1, 2026

6. Stopped

   Nivolumab and Ipilimumab With and Without Camu Camu · Metastatic…Nivolumab and Ipilimumab With and Without Camu Camu · Metastatic Renal Cell Carcinoma

   Trial status changed: Active, Not Recruiting → Suspended

   City of Hope Medical Center·Phase 1· NCT06049576· Registry history of NCT06049576 on ClinicalTrials.gov (opens the registry)

   Oct 2, 2026

7. Notable

   Atezolizumab Alone or Atezolizumab Plus Bevacizumab · Advanced…Atezolizumab Alone or Atezolizumab Plus Bevacizumab · Advanced Alveolar Soft Part Sarcoma

   Primary and study completion pushed from Oct 31, 2026 to Oct 31, 2027

   National Cancer Institute (NCI)·Phase 2· NCT03141684· Registry history of NCT03141684 on ClinicalTrials.gov (opens the registry)

   Oct 14, 2026

8. Notable

   Vactosertib in Adolescents and · Recurrent, Refractory or…Vactosertib in Adolescents and · Recurrent, Refractory or Progressive Osteosarcoma

   Primary completion pushed from Sep 2025 to Dec 2027

   Also in this update: Enrollment increased: 48 → 78 participants; Trial sites expanded: 3 → 7 locations

   MedPacto, Inc.·Phase 1/2· NCT05588648· Registry history of NCT05588648 on ClinicalTrials.gov (opens the registry)

   Oct 7, 2026

9. Notable

   Cabozantinib S-malate and Nivolumab With or Without Ipilimumab…Cabozantinib S-malate and Nivolumab With or Without Ipilimumab · Metastatic Genitourinary Tumors

   Primary and study completion pushed from Sep 30, 2026 to Jul 30, 2027

   National Cancer Institute (NCI)·Phase 1· NCT02496208· Registry history of NCT02496208 on ClinicalTrials.gov (opens the registry)

   Oct 15, 2026

10. Notable

    STARTRK-NG · Entrectinib (Rxdx-101) in Children and · Locally…STARTRK-NG · Entrectinib (Rxdx-101) in Children and · Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

    Primary and study completion pushed from Jun 30, 2026 to Jun 30, 2027

    Hoffmann-La Roche·Phase 1/2· NCT02650401· Registry history of NCT02650401 on ClinicalTrials.gov (opens the registry)

    Sep 23, 2026

11. Notable

    Fluorescence-Guided Surgical Resection for Reducing Unexpected…Fluorescence-Guided Surgical Resection for Reducing Unexpected Positive Margins · Sarcoma, SarcoSIGHT Trial

    Primary and study completion pushed from May 11, 2028 to Dec 17, 2029

    City of Hope Medical Center·Phase 2· NCT07650656· Registry history of NCT07650656 on ClinicalTrials.gov (opens the registry)

    Oct 16, 2026

12. Notable

    BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial…BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment

    Primary and study completion pushed from Sep 2026 to Sep 2027

    Memorial Sloan Kettering Cancer Center·Phase 2· NCT04106414· Registry history of NCT04106414 on ClinicalTrials.gov (opens the registry)

    Oct 16, 2026

13. Notable

    CLOVER-2 · CLR 131 in Pediatric Relapsed/Refractory Malignant…CLOVER-2 · CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas

    Primary completion pushed from Aug 25, 2026 to Jun 30, 2027

    Also in this update: Study completion pushed from Feb 25, 2027 to Dec 2027

    Cellectar Biosciences, Inc.·Phase 1· NCT03478462· Registry history of NCT03478462 on ClinicalTrials.gov (opens the registry)

    Oct 1, 2026

14. Notable

    ANTARES · Agnostic Therapy in Rare Solid Tumors

    Primary completion pushed from Jul 2026 to Jul 2027

    Also in this update: Enrollment closed, study ongoing; Trial sites reduced: 8 → 5 locations

    Instituto do Cancer do Estado de São Paulo·Phase 2· NCT06638931· Registry history of NCT06638931 on ClinicalTrials.gov (opens the registry)

    Oct 13, 2026

15. Notable

    Blended e-Health Intervention to Improve Fear of Progression…Blended e-Health Intervention to Improve Fear of Progression · Gynecologic or Breast Cancer

    Primary and study completion pushed from Jan 16, 2028 to Aug 6, 2028

    City of Hope Medical Center·Not applicable· NCT07741968· Registry history of NCT07741968 on ClinicalTrials.gov (opens the registry)

    Oct 16, 2026

16. Notable

    Use of Educational Videos in Newly Diagnosed Patients in a Medical…Use of Educational Videos in Newly Diagnosed Patients in a Medical Oncology Sarcoma Clinic

    Primary and study completion pushed from Apr 2026 to Dec 2027

    Mount Sinai Hospital, Canada·Not applicable· NCT06805773· Registry history of NCT06805773 on ClinicalTrials.gov (opens the registry)

    Oct 14, 2026

17. Notable

    Ipilimumab and Nivolumab Combination With or Without Cabozantinib…Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma

    Primary and study completion pushed from May 15, 2026 to May 15, 2028

    National Cancer Institute LAO·Phase 2· NCT05836571· Registry history of NCT05836571 on ClinicalTrials.gov (opens the registry)

    Oct 9, 2026

18. Notable

    Blood and Tissue Extraction for Immunological Examinations During…Blood and Tissue Extraction for Immunological Examinations During Neoadjuvant Therapy of Soft Tissue Sarcomas

    Primary completion pushed from Jul 21, 2026 to Dec 31, 2028

    Also in this update: Enrollment closed, study ongoing; Study completion moved earlier from Jul 21, 2031 to Dec 31, 2028

    University Hospital Tuebingen·Not applicable· NCT06385288· Registry history of NCT06385288 on ClinicalTrials.gov (opens the registry)

    Oct 13, 2026

19. Notable

    SARC041 · Abemaciclib Versus Placebo · Advanced Dedifferentiated…SARC041 · Abemaciclib Versus Placebo · Advanced Dedifferentiated Liposarcoma

    Primary completion pushed from Dec 2025 to Dec 2027

    Also in this update: Study completion pushed from Dec 2026 to Dec 2027

    Sarcoma Alliance for Research through Collaboration·Phase 3· NCT04967521· Registry history of NCT04967521 on ClinicalTrials.gov (opens the registry)

    Oct 5, 2026

20. Notable

    Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo · Stage…Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo · Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

    Primary and study completion pushed from Dec 31, 2027 to Apr 23, 2029

    Mayo Clinic·Phase 2· NCT06639074· Registry history of NCT06639074 on ClinicalTrials.gov (opens the registry)

    Oct 2, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.